期刊文献+

血清Gal-1、GPX3对分化型甲状腺癌术后^(131)Ⅰ清甲治疗效果的评估价值 被引量:3

Evaluation value of serum Gal-1 and GPX3 on the therapeutic effect of ^(131)Ⅰ treatment after differentiated thyroid cancer surgery
下载PDF
导出
摘要 目的:探究血清半乳糖凝集素-1(Gal-1)、谷胱甘肽过氧化物酶3(GPX3)对分化型甲状腺癌(DTC)术后^(131)I清甲治疗效果的评估价值。方法:106例DTC术后行^(131)I清甲治疗患者,根据术后6个月疗效将患者分为疗效满意(ER)组和疗效不满意(non-ER)组。收集两组一般资料及血清Gal-1、GPX3等生化指标水平,用单因素及Logistic回归模型分析各项指标与^(131)I清甲疗效的关系;用受试者工作特征曲线(ROC)分析血清Gal-1、GPX3对^(131)I清甲疗效的评估价值。结果:106例患者中,^(131)I治疗7 d后,清甲成功率为74.53%(79/106);术后6个月后,疗效ER者62例,入ER组,疗效non-ER者44例,入non-ER组。与non-ER组相比,ER组TSH、刺激性Tg、Gal-1水平均较低,Gal-1水平较高(P<0.05)。Logistic回归分析显示,TSH(OR=0.456)、刺激性Tg(OR=0.434)、Gal-1(OR=1.919)、GPX3(OR=0.494)均是^(131)I清甲疗效的独立影响因素(P<0.05)。ROC曲线分析显示,血清Gal-1、GPX3评估^(131)I清甲疗效的曲线下面积(AUC)分别为0.754、0.861;且以二者联合的诊断效能最大(AUC=0.956,敏感度=97.73%、特异度=83.87%)。结论:血清Gal-1、GPX3水平与^(131)I清甲疗效密切相关,二者联合用于DTC术后^(131)I清甲疗效评估具有一定参考价值。 Objective:To explore the evaluation value of serum galactose lectin-1(Gal-1)and glutathione peroxidase 3(GPX3)on the efficacy of ^(131)I treatment after differentiated thyroid carcinoma(DTC).Methods:A total of 106 patients with DTC who underwent ^(131)I treatment after operation,according to the curative effect after 6 months,the patients were divided into satisfactory curative effect(ER)group and unsatisfactory curative effect(non-ER)group.The general data and serum levels of Gal-1,GPX3 and other biochemical indicators were collected.The relationship between various indicators and the efficacy of ^(131)I treatment was analyzed by single factor and Logistic regression model.The evaluation value of serum Gal-1 and GPX3 on the efficacy of ^(131)I treatmente was analyzed by receiver operating characteristic curve(ROC).Results:Among 106 patients,the success rate of ^(131)I treatment was 74.53%(79/106)after 7 days of treatment.6 months later,62 patients achieved ER were enrolled in the ER group,44 patients achieved non-ER were enrolled in the non-ER group.Compared with non-ER group,TSH,stimulating Tg and Gal-1 levels in ER group were significantly lower,while Gal-1 level was significantly higher(P<0.05).Logistic regression analysis showed that TSH(OR=0.456),stimulating Tg(OR=0.434),Gal-1(OR=1.919)and GPX3(OR=0.494)were independent influencing factors of ^(131)I treatment effect(P<0.05).ROC curve analysis showed that the area under the curve(AUC)of serum Gal-1 and GPX3 were 0.754 and 0.861,respectively.The combination of the two had the highest diagnostic efficiency[AUC=0.956,sensitivity=97.73%,specificity=83.87%].Conclusion:Serum Gal-1 and GPX3 levels are closely related to the efficacy of ^(131)I treatment,and the combination of the two has a certain reference value for the evaluation of the efficacy of ^(131)I treatment after DTC.
作者 刘映华 符国宏 郑杨慈 蔡西婷 LIU Ying-hua;FU Guo-hong;ZHENG Yang-ci;CAI Xi-ting(Department of Quality Control,Haikou Hospital of the Maternal and Child Health,Haikou 571100;Department of General Surgery,Sanya Central Hospital,Sanya 572000,Hainan,China)
出处 《川北医学院学报》 CAS 2022年第11期1451-1454,共4页 Journal of North Sichuan Medical College
基金 海南省卫生健康行业科研项目(20A200539)。
关键词 半乳糖凝集素-1 谷胱甘肽过氧化物酶3 甲状腺癌 放射疗法 疗效评估 Galactose lectin-1 Glutathione peroxidase 3 Thyroid cancer Radiotherapy Efficacy evaluation
  • 相关文献

参考文献11

二级参考文献79

  • 1Davies L,Welch HG.Increasing incidence of thyroid cancer in the United States,1973-2002.J Am Med Assoc,2006,295:2164-2167. 被引量:1
  • 2Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16:109-142. 被引量:1
  • 3Lundgren CI,Hall P,Dickman PW,et al.Clinically significant prognostic factors for differentiated thyroid carcinoma:a populationbased,nested case-control study.Cancer,2006,106:524-531. 被引量:1
  • 4Jukkola A,Bloigu R,Ebeling T,et al.Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications.Endocr Relat Cancer,2004,11:571-579. 被引量:1
  • 5Bilimoria KY,Bentrem DJ,Ko CY,et al.Extent of surgery affects survival for papillary thyroid cancer.Ann Surg,2007,246:375-381. 被引量:1
  • 6Do MY,Rhee Y,Kim DJ,et al.Clinical features of bone metastases resulting from thyroid cancer:a review of 28 patients over a 20-year period.Endocr J,2005,52:701-707. 被引量:1
  • 7Kumar A,Bal CS.Differentiated thyroid cancer.Indian J Pediatr,2003,70:707-713. 被引量:1
  • 8Mazzaferri EL,Robbins RJ,Spencer CA,et al.A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.J Clin Endocrinol Metab,2003,88:1433-1441. 被引量:1
  • 9Kim TY,Kim WB,Kim ES,et al.Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.J Clin Endocrinol Metab,2005,90:1440-1445. 被引量:1
  • 10Spencer CA,Bergoglio LM,Kazarosyan M,et al.Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas.J Clin Endocrinol Metab,2005,90:5566-5575. 被引量:1

共引文献352

同被引文献34

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部